Immunitor, Inc.

NEW YORK, NY / ACCESSWIRE / March 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarify the Company's corporate focus, direction, and progress. Also, for the public to better understand the Company, its mission, and its opportunity. Following management change and Company repositioning, there has been substantial progress as has been advised through press releases. However, following recent inquiries, Key Capital clarifies that its primary focus is to progress its partnered Immunitor therapeutic vaccines through to formal registrations. Cancer Vaccines - Immunitor V5 Series: The Immunitor cancer vaccines are the Company's primary focus, as they have already demonstrated treatment success in late stage and terminal cases of liver cancer as well as in other cancers. As has previously been reported, there is no immunotherapy product in the market that even comes close to the 12-month over 90% survival rate achieved in 75 patients in an Open-label Phase II advanced hepatocellular carcinoma (HCC) clinical trial. Similar success has been reported by Immunitor in other cancers through its peer-reviewed publications and extensive patent documentation, including in breast, cervical/uterine, prostate, brain tumors and leukemia. Significantly, in each case the affordable Immunitor V5 Series therapeutic vaccines were administered as daily oral pills that demonstrated no side effects. Affirming the safety, mechanism and performance of the Immunitor therapeutic vaccines for cancer in Western-standard clinical studies is now the single objective in order that regulatory product approvals are achieved. Implementation: Key Biotec, a division of Key Capital, is leading the renewed research initiatives in its partnering with Immunitor. A CRO is in process of being secured to run the clinical trials, globally recognized scientists are joining the existing team as well as being appointed in advisory positions, the clinical trial strategy is being formulated with focus on the Immunitor V5 FDA Orphan Drug designated HCC candidate, up to US$30 million in development funding is being progressed with a number of interested parties through Key Biotec, and Key Capital will also complete a small Private Placement to supplement working capital. Revenue Generation: While the cancer treatment research is being progressed, Key Capital will commence revenue generation as from the 2021 second quarter. This will be achieved through the global launch of two significant dietary supplements the Company has partnered with Immunitor, and through the distribution of a range of unique natural health and antiaging products. The first 50,000 supplement doses of each supplement have already been formulated, manufactured, and certified at Immunitor's GMP facility in Thailand in preparation for their respective launches. Mental Health Supplement - MaxCellLife MIND: MaxCellLife MIND is a breakthrough all-natural dietary supplement launching in the US$18 billion anxiety and stress mental health product market. MaxCellLife MIND is designed to support the body naturally dealing with the challenges of stress, anxiety, and depression. MIND is a unique proprietary M.vaccae and ionic Magnesium combination MIND uses the Immunitor patented oral pill delivery technology assuring delivery to the heart of the body's immune system in the gut, without it being degraded. M.vaccae is a unique natural probiotic that many studies report support its potential for activation of increased serotonin levels, that in turn may improve mood. The major challenge of how to get sufficient M.vaccae and proprietary ionic magnesium to the gut was resolved through leveraging our partnered Immunitor patented oral pill technology. MaxCellLife MIND provides natural support for stress and anxiety without side effects. The Company is also pleased to advise that response to date from a small population of largely university students that have been trying MaxCellLife MIND is overwhelmingly positive. Immune Supplement - MaxCellLife 24/7 IMMUNE: WHO advises up to 650,000 people die annually due to flu which helps fuel demand for cold and flu supplements to boost immunity in a market forecast to grow to over US$23 billion in the next 5 years. The current coronavirus pandemic has accelerated demand for cold and flu supplements with the Asian region accounting for over 35% of this growing market. As is well known, the immune system is the body's first line of defense against infection by viruses, bacteria, and other pathogens. Magnesium is one of the immune system's critically needed minerals, and it is widely reported that around 50% of the western population is deficient in magnesium, which in turn means their immune systems are likely compromised to some degree. It is also known that the immune system, as well as magnesium independently, supports natural ribosome instruction that helps to create, repair, and protect DNA and proteins. So, introducing 24/7 IMMUNE, the powerful Immunitor ionic form of magnesium directly to the heart of the immune system gut mucosa, may well support natural immunity function. Preliminary independent laboratory tissue culture testings, through a leading Asian research institute have also affirmed that the 24/7 IMMUNE magnesium compound is safe and may strengthen antiviral defense, including against COVID-19 for which it has been successfully independently tested. It is noted that the USA CDC advice on "COVID-19 and Nutrition for Health" includes: "Dietary supplements aren't meant to treat or prevent COVID-19. Certain vitamins and minerals may have effects on how our immune system works to fight off infections, as well as inflammation and swelling." As previously reported, Company Chairman, Peter Boonen has stated, "Magnesium is critical for and supports healthy immunity, and we have significant expectancy for our unique 24/7 IMMUNE magnesium supplement. But it is important to understand that this supplement is not a medicine or treatment for COVID-19 or any disease or other medical condition. While we believe it beneficial to supplement the immune system with our supplements, we strongly advise any person with a medical condition to seek and follow advice from their healthcare professional." Status of Quotation on OTC Markets: The Company has engaged an experienced accounting professional who has been working to finalize the Key Capital delinquent quarterly and Annual accounts for the past two and a quarter year period. These accounts are expected to be lodged in the next quarter, along with quotation application and payment of annual OTC Markets fees. It is expected that this will provide for the Company's securities to be again quoted by market makers. Immunitor: Immunitor, Key Capital's Licensor and Partner is well recognized globally as a pioneer in oral vaccines development. Immunitor has been researching and developing oral pill vaccines for over two decades and has reported game changing success in human clinical trials in HCC Liver Cancer and many other medical conditions, that have been extensively published in leading peer reviewed medical journals. Key Capital Corporation: The Company's focus is on the further development of its oral pill therapeutic vaccines through its Key Biotec and Immunitor partnering, particularly on advancing the highly-promising FDA Orphan Drug Designated V5 HCC liver cancer candidate. Additionally, where products can be marketed as supplements, the Company will actively explore these options. For further information see: and - and for all inquiries please contact: Key Capital at +1 (646) 401-0177, or Peter Boonen, Chairman, at peter@keycapitalcorp.com References: Notice: The statements made in this Press Release, or on our websites, and in or on any of our product packaging have not been evaluated by the FDA or any other global authority or regulatory body. The magnesium immune products are not intended or represented to diagnose, treat, cure, or prevent any disease or health condition. The information provided in this Press Release, or on our websites, and in or on any of our product packaging, is for informational purposes and not intended as medical advice, which in all cases should always be obtained from your doctor or other qualified health care professional. Disclaimer: Statements made in this press release that express the Company or management's intentions, plans, beliefs, expectations, or predictions of future events, are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company's actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results, levels of activity, performance or achievements and investors should not place undue reliance on the Company's forward-looking statements. SOURCE: Key Capital Corporation View source version on accesswire.com:

NEW YORK, NY / ACCESSWIRE / January 6, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis. While WHO advocates that: "no one is safe until everyone is safe", their COVAX facility viability is being questioned, with major cities and countries in various stages of lockdown, hospitals overwhelmed and sadly, as reported by the World Bank, this year will see COVID-19 responsible for as many as150 million people relegated to extreme poverty (living on less than US$1.90 / day). Millions will die from starvation. Key Capital Chairman, Peter Boonen today stated: "The need to vaccinate the world population is unprecedented, and the flawed and troubled WHO COVAX approach will go nowhere near resolving the global crisis or providing fair and equitable access for all. Most of the world's poor countries cannot afford the vaccine and the countrywide vaccination costs, and GAVI is reported to now requiring minimum payments from these poor countries as well." He further advised: "What the world urgently needs is a simple affordable room temperature stable vaccine that can be readily and economically mass distributed with minimal administration costs. If an affordable easily mass distributed solution is not found re-infection will continue and as advised by GAVI, the virus impact would then continue unabated." For the record, the WHO and GAVI driven COVAX vaccine facility has been established to purportedly provide everyone, and especially the world's poor countries, fair and equitable access to COVID-19 vaccines. The Global Alliance for Vaccines and Immunizations (GAVI) website advises: "It is the only truly global solution to this pandemic because it is the only effort to ensure that people in all corners of the world will get access to COVID-19 vaccines once they are available, regardless of their wealth." Adding that the COVAX facility is necessary because: "without it there is a very real risk that the majority of people in the world will go unprotected against SARS-CoV-2, and this would allow the virus and its impact to continue unabated." The reality is that COVAX is not providing any "truly global solution to this pandemic". As the virus mutates, and daily infections, hospitalizations, and deaths increase, current therapeutic options remain limited, and global vaccination is simply not a reality, even within a 5-year timeframe under current circumstances. Key Capital believes its COVID-19 oral pill therapeutic vaccine can meet the pandemic challenges by offering therapeutic treatment options and a highly efficient global mass vaccination option, which is what motivates Key Capital to seek funding partners for its COVID-19 vaccine opportunity. Key Capital believes its oral pill vaccine and similar options such as the iavi/Merck collaboration, Vaxart, and the promising MK-4482/EIDD/2801 being tested by the Institute for Biomedical Sciences at Georgia State University, should all be aggressively pursued, as oral vaccines can very rapidly: Provide for the most expedient mass manufacture and mass distribution Inhibit COVID-19 progression to severe disease Shorten infected and infectious disease stages Contain local and larger outbreaks Prove to be gamechangers in the global vaccination solution Key Capital encourages inquiry from parties having an interest to partner funding to support the clinical trials required to achieve marketing approvals for its COVID-19 therapeutic Vaccine. About Key Capital Therapeutic Vaccines: To the Company's knowledge, its vaccine products are the only products demonstrating success as an oral vaccine to treat terminal and late-stage cancers, TB, and other serious conditions - and the only known therapeutic immunotherapy vaccine treatment available as a simple pill without side effects. Of specific significance in the case of the oral pill vaccine application to COVID-19 is that almost all infectious viruses enter the host through mucous membranes. Therefore, mucosal immunity, rather than systemic, is regarded as essential to maximally protect against any such transmitted pathogens. Key Capital Business Focus: As advised in previous announcements, the Company will in association with Immunitor Inc, remain focused and seek to fast-track further clinical studies and regulatory approval of the FDA Orphan Drug Designated Immunitor V5 as a development priority. The Company is additionally offering the COVID-19 therapeutic vaccine partnering opportunity as there is a clear and urgent global need for a simple, affordable, and easily mass-distributable COVID-19 treatment, and significantly, the Key Capital COVID-19 oral pill therapeutic vaccine has already been developed and is currently being tested in several Asian locations. Current Liver Cancer (HCC) Situation and Options: There is urgent need for an effective liver cancer treatment, as its incidence is increasing affecting over 800,000 people annually with a high mortality rate of about 700,000 per year, and treatment options being prohibitively expensive. In most patients, by the time HCC is diagnosed, surgical intervention or liver transplants are often not feasible, and conventional systemic chemotherapies have poor response success and are quite systemically toxic. None of the currently approved or experimental HCC drugs are free from adverse side effects, nor have they secured significant success in treatment or shrinking tumors. Keytruda for example, aside from its high cost, only has a 10% positive response rate in 12-month HCC treatments. Breakthrough Liver Cancer Treatment Immunitor V5 has demonstrated unparalleled success in all clinical studies to date for the treatment of liver cancer, which is predominantly hepatocellular carcinoma (HCC). In a phase 2 randomized placebo control clinical study reported in February 2017 peer-reviewed open access Journal of Hepatocellular Carcinoma, of 75 patients with late-stage or inoperable HCC, over 90% were responsive to the oral V5 treatment and alive after a median 12 months of follow up - by comparison only about 10% are responsive after one year of treatment with Nexavar. Key Capital Corporation: The Company's immediate objective is the further development of the oral pill therapeutic vaccine opportunity through its Key Biotec and Immunitor partnering, particularly on advancing the Orphan Drug Designated V5 liver cancer candidate. For further information see: and . For all inquiries please contact: Key Capital at +1 (646) 401-0177, or Peter Boonen, Chairman, at peter@keycapitalcorp.com. References: Disclaimer: Statements made in this press release that express the Company or management's intentions, plans, beliefs, expectations, or predictions of future events, are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will" and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company's actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results, levels of activity, performance or achievements and investors should not place undue reliance on the Company's forward-looking statements. SOURCE: Key Capital Corporation View source version on accesswire.com: